Mosquito Borne Diseases Market Report 2026

The mosquito borne diseases market size has grown strongly in recent years. It will grow from $3.3 billion in 2025 to $3.57 billion in 2026 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to climate-driven mosquito expansion, limited access to vaccines, high burden in tropical regions, dependence on government eradication programs, rising incidence of dengue and malaria.

The mosquito borne diseases market size is expected to see strong growth in the next few years. It will grow to $4.81 billion in 2030 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to emerging genetic control technologies, expanding vaccination programs, increasing global health funding, rapid adoption of digital disease surveillance, rising demand for advanced mosquito control products. Major trends in the forecast period include rising demand for precision vector surveillance, increased use of AI-powered disease prediction models, expansion of iot-based mosquito monitoring systems, growth in eco-friendly and sustainable vector control solutions, integration of digital health platforms for remote disease tracking.

The surge in international travel is expected to drive the growth of the mosquito-borne diseases market in the coming years. Increased travel for leisure, business, and family reunions post-pandemic, combined with improved accessibility and travel infrastructure, has heightened human exposure to mosquito habitats. This facilitates the movement of disease-carrying mosquitoes and complicates effective vector control measures. For example, in September 2024, according to UN Tourism, a Spain-based tourism agency, approximately 1.1 billion international tourist arrivals were recorded from January to September 2024, representing an 11% increase compared to the same period in 2023. Therefore, the rise in international travel is fueling growth in the mosquito-borne diseases market.

Key companies in the mosquito-borne diseases market are focusing on technological innovations, such as advanced mosquito repellents, to improve protection against diseases like malaria, dengue, and Zika. Advanced mosquito repellents use long-lasting, effective ingredients or technologies - such as microencapsulation, natural compounds, or wearable devices - to provide enhanced defense against mosquitoes. For instance, in March 2023, Mortein, an Australia-based household insecticide brand, launched Mortein Smart+, a liquid vaporizer offering two hours of residual protection even after being turned off. This product demonstrates Mortein’s commitment to providing reliable solutions for families and combating the rising threat of mosquito-borne diseases.

In February 2024, Kao Corporation, a Japan-based chemicals company, partnered with Earth Corporation to address mosquito-borne diseases in Thailand. Together, they introduced the ARS Mos Shooter, an eco-friendly spray formulated with advanced surfactant technology and lemongrass essential oil to disrupt mosquito flight. The initiative aims to reduce dengue fever incidence by promoting public health awareness and community engagement. Earth Corporation, also Japan-based, manufactures and sells household products and insecticides and is actively involved in addressing mosquito-borne infectious diseases.

Major companies operating in the mosquito borne diseases market are Johnson & Johnson, Merck & Co Inc, Sanofi SA, Novartis AG, GlaxoSmithKline plc, Serum Institute of India Pvt Ltd, Emergent BioSolutions, Valneva SE, Bharat Biotech, Syngenta, Orkin Inc, RTI International, Vector Control International, Clarke Environmental Mosquito Management, Oxitec Ltd, Abbott Laboratories, Takeda Pharmaceuticals, Sun Pharmaceutical Industries Ltd, Pfizer Inc, Roche Holding AG, Moderna Inc, BioNTech SE, CSL Limited, Bayer AG, BASF SE.

North America was the largest region in the mosquito borne diseases market in 2025. Latin America is expected to be the fastest-growing region in the forecast period. The regions covered in the mosquito borne diseases market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the mosquito borne diseases market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs on chemicals, medical supplies, and diagnostic equipment have increased production and import costs for mosquito control solutions, affecting medications, vector control tools, and testing kits. Regions heavily reliant on imported insecticides - such as parts of Africa, Asia, and Latin America - experience higher operational expenses and slower intervention responses. However, tariffs have encouraged local manufacturing and innovation in eco-friendly vector control technologies, enabling some markets to reduce dependency on foreign suppliers.

The mosquito borne diseases market research report is one of a series of new reports that provides mosquito borne diseases market statistics, including mosquito borne diseases industry global market size, regional shares, competitors with a mosquito borne diseases market share, detailed mosquito borne diseases market segments, market trends and opportunities, and any further data you may need to thrive in the mosquito borne diseases industry. This mosquito borne diseases market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Mosquito-borne diseases are a group of infectious illnesses caused by parasites, viruses, or bacteria transmitted to humans through the bites of infected female mosquitoes. These diseases pose significant public health challenges, contributing to high morbidity and mortality rates and emphasizing the need for effective prevention and control measures in both endemic and non-endemic regions worldwide.

The main types of mosquito-borne diseases include malaria, dengue, yellow fever, West Nile virus, chikungunya, Zika virus, and others. Malaria is an infectious disease caused by parasites of the genus Plasmodium, transmitted to humans through bites from infected female Anopheles mosquitoes. Treatment approaches include medications, vaccination, vector control strategies, immunotherapy, supportive care, and other methods, serving a variety of end users such as hospitals, clinics, diagnostic centers, research institutes, government organizations, non-governmental organizations, and others.

The mosquito borne diseases market consists of sales of insecticide-treated bed nets, antimalarial medications, adult mosquito control products, diagnostic kits, and protective clothing. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.